Results from the second head to head trial of MAT
Post# of 63
(Total Views: 344)
Posted On: 12/24/2020 4:53:12 PM
Results from the second head to head trial of MAT 9001 vs Vascepa will be announced in 1Q 2021. If, as expected, MAT 9001 again proves to be much more effective than Vascepa in lowering triglycerides, and PCSK9 levels, that alone should boost the price at least 3X.
Then there are the ongoing trials for the LNC formulations of amphotericin b and amikacin, that are being funded by the NIH and CF Foundation, respectively, either of which, if successful, could catapult the SP of the stock.
And of course, MTNB is in collaboration with numerous BP companies including Gilead, Sanofi, and Regeneron, each of which has asked MTNB to encochleate their drugs to make them safer and orally available.
If even one of these BP trials proves to be successful, MTNB could be acquired at a huge premium to its current SP.
Management comes from BP, including its chairman, Herb Conrad, who was president of Roche, and know how to get drugs approved, and a company sold.
Dangerous short.
Then there are the ongoing trials for the LNC formulations of amphotericin b and amikacin, that are being funded by the NIH and CF Foundation, respectively, either of which, if successful, could catapult the SP of the stock.
And of course, MTNB is in collaboration with numerous BP companies including Gilead, Sanofi, and Regeneron, each of which has asked MTNB to encochleate their drugs to make them safer and orally available.
If even one of these BP trials proves to be successful, MTNB could be acquired at a huge premium to its current SP.
Management comes from BP, including its chairman, Herb Conrad, who was president of Roche, and know how to get drugs approved, and a company sold.
Dangerous short.
(1)
(0)Matinas BioPharma Holdings (MTNB) Stock Research Links
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
Scroll down for more posts ▼